ARWR
Price
$32.80
Change
+$1.13 (+3.57%)
Updated
Sep 26, 04:59 PM (EDT)
Capitalization
4.53B
65 days until earnings call
PBIGF
Price
$0.18
Change
+$0.01 (+5.88%)
Updated
Sep 16 closing price
Capitalization
73.23M
Interact to see
Advertisement

ARWR vs PBIGF

Header iconARWR vs PBIGF Comparison
Open Charts ARWR vs PBIGFBanner chart's image
Arrowhead Pharmaceuticals
Price$32.80
Change+$1.13 (+3.57%)
Volume$40.51K
Capitalization4.53B
Paradigm Biopharmaceuticals
Price$0.18
Change+$0.01 (+5.88%)
Volume$2.25K
Capitalization73.23M
ARWR vs PBIGF Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. PBIGF commentary
Sep 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a StrongBuy and PBIGF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 27, 2025
Stock price -- (ARWR: $32.79 vs. PBIGF: $0.18)
Brand notoriety: ARWR: Notable vs. PBIGF: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 35% vs. PBIGF: 26%
Market capitalization -- ARWR: $4.53B vs. PBIGF: $73.23M
ARWR [@Biotechnology] is valued at $4.53B. PBIGF’s [@Biotechnology] market capitalization is $73.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $98.9B to $0. The average market capitalization across the [@Biotechnology] industry is $1.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whilePBIGF’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • PBIGF’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than PBIGF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while PBIGF’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 3 bearish.
  • PBIGF’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than PBIGF.

Price Growth

ARWR (@Biotechnology) experienced а +6.86% price change this week, while PBIGF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.14%. For the same industry, the average monthly price growth was +9.25%, and the average quarterly price growth was +54.64%.

Reported Earning Dates

ARWR is expected to report earnings on Dec 01, 2025.

Industries' Descriptions

@Biotechnology (+4.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($4.54B) has a higher market cap than PBIGF($73.2M). ARWR YTD gains are higher at: 74.441 vs. PBIGF (-33.169). PBIGF has higher annual earnings (EBITDA): -15.46M vs. ARWR (-52.51M).
ARWRPBIGFARWR / PBIGF
Capitalization4.54B73.2M6,195%
EBITDA-52.51M-15.46M340%
Gain YTD74.441-33.169-224%
P/E RatioN/AN/A-
Revenue573MN/A-
Total Cash900MN/A-
Total Debt353MN/A-
FUNDAMENTALS RATINGS
ARWR vs PBIGF: Fundamental Ratings
ARWR
PBIGF
OUTLOOK RATING
1..100
2224
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3565
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/a17

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBIGF's Valuation (86) in the null industry is in the same range as ARWR (94) in the Biotechnology industry. This means that PBIGF’s stock grew similarly to ARWR’s over the last 12 months.

PBIGF's Profit vs Risk Rating (100) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that PBIGF’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (97) in the Biotechnology industry is in the same range as PBIGF (98) in the null industry. This means that ARWR’s stock grew similarly to PBIGF’s over the last 12 months.

ARWR's Price Growth Rating (35) in the Biotechnology industry is in the same range as PBIGF (65) in the null industry. This means that ARWR’s stock grew similarly to PBIGF’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PBIGF (100) in the null industry. This means that ARWR’s stock grew significantly faster than PBIGF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRPBIGF
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
29%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
65%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
37%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
35%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
39%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
47%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
25%
Aroon
ODDS (%)
Bullish Trend 2 days ago
73%
Bearish Trend 2 days ago
54%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBIGF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MCEFX14.09N/A
N/A
BlackRock International Select Eq Inv C
NEOYX34.71N/A
N/A
Natixis Oakmark Y
CMLCX61.07N/A
N/A
American Funds American Mutual 529C
NMVLX12.13N/A
N/A
Nuance Mid Cap Value Institutional
SPMQX6.08N/A
N/A
Invesco SteelPath MLP Income R5

PBIGF and

Correlation & Price change

A.I.dvisor indicates that over the last year, PBIGF has been loosely correlated with ABEO. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if PBIGF jumps, then ABEO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBIGF
1D Price
Change %
PBIGF100%
N/A
ABEO - PBIGF
34%
Loosely correlated
+1.31%
STTK - PBIGF
21%
Poorly correlated
-0.44%
ARWR - PBIGF
21%
Poorly correlated
+3.58%
OXBDF - PBIGF
7%
Poorly correlated
N/A
PTCHF - PBIGF
6%
Poorly correlated
N/A
More